References
- Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA. Cancer J Clin. [Internet]. 2015;65:87–108. Available from: http://onlinelibrary.wiley.com/doi/10.3322/caac.21262/abstract
- Hammerman PS, Neil Hayes D, Grandis JR. Therapeutic insights from genomic studies of head and neck squamous cell carcinomas. Cancer Discov. 2015;5:239–244.
- Hayes DN, Van Waes C, Seiwert TY. Genetic landscape of human papillomavirus-associated head and neck cancer and comparison to tobacco-related tumors. J Clin Oncol. [Internet]. 2015;33:3227–3234. Available from: http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2015.62.1086
- Ferris RL. Immunology and immunotherapy of head and neck cancer. J Clin Oncol. [Internet]. 2015;33:3293–3304. Available from: http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2015.61.1509
- Bruce JP, Yip K, Bratman SV, et al. Nasopharyngeal cancer: molecular landscape. J Clin Oncol. [Internet]. 2015;33:3346–3355. Available from: http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2015.60.7846
- Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. [Internet]. 2015;517:576–582. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25631445
- Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. [Internet]. 2005 [cited 2013 Nov 25];27:843–850. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16161069
- Pignon J-P, le Maître A, Bourhis J. Meta-analyses of chemotherapy in head and neck cancer (MACH-NC): an update. Int J Radiat Oncol Biol Phys. [Internet]. 2007 [cited 2013 Nov 28];69:S112–4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17848275
- Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. [Internet]. 2010 [cited 2013 Sep 18];11:21–28. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19897418
- Blanchard P, Baujat B, Holostenco V, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol. [Internet]. 2011 [cited 2014 Jun 6];100:33–40. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21684027
- Blanchard P, Lee A, Marguet S, et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol. [Internet]. 2015;16:645–655. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1470204515701269
- Sun Y, Li W-F, Chen N-Y, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016;17:1509–1520. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1470204516304107
- Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. [Internet]. 2008 [cited 2015 Jan 6];359:1116–1127. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18784101
- Zhang L, Huang Y, Hong S, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet [Internet]. 2016;388:1883–1892. Available from.
- Ferris RL, Blumenschein G, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. [Internet]. 2016;375:1856–1867. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1602252
- Cohen EE, Harrington KJ, Le Tourneau C, et al. LBA45_PRPembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): phase 3 KEYNOTE-040 trial. Ann Oncol. [Internet]. 2017;28. Available from: http://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx440.040/4109952/LBA45PRPembrolizumab-pembro-vs-standard-of-care
- Hsu C, Lee S-H, Ejadi S, et al. Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1–positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study. J Clin Oncol. [Internet]. 2017;35:JCO.2017.73.367. Available from: http://ascopubs.org/doi/10.1200/JCO.2017.73.3675
- Machiels J-PH, Haddad RI, Fayette J, et al. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol. [Internet]. 2015;16:583–594. Available from: http://www.sciencedirect.com/science/article/pii/S1470204515701245
- Soulières D, Faivre S, Mesía R, et al. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncol. [Internet]. 2017;18:323–335. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28131786
- Massarelli E, Lin H, Ginsberg LE, et al. Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2015;26:1476–1480.
- Geiger JL, Bauman JE, Gibson MK, et al. Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma. Head Neck. [Internet]. 2016;38:1759–1764. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27232378
- Dunn LA, Fury MG, Xiao H, et al. A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Ann Oncol. 2017;28:2533–2538.
- Santuray RT, Johnson DE, Grandis JR. New therapies in head and neck cancer. Trends Cancer [Internet]. 2018;4:385–396. Available from.
- Elicin O, Ozsahin M. The latest prospects of investigational drugs for head and neck cancer. Expert Opin Investig Drugs. [Internet]. 2017;26:265–268. Available from. https://www.tandfonline.com/doi/full/10.1080/13543784.2017.1279145
- Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. [Internet]. 2006;354:567–578. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3638633&tool=pmcentrez&rendertype=abstract
- Lee SC, López-Albaitero A, Ferris RL. Immunotherapy of head and neck cancer using tumor antigen-specific monoclonal antibodies. Curr Oncol Rep. [Internet]. 2009;11:156–162. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19216848
- Ou D, Levy A, Blanchard P, et al. Concurrent chemoradiotherapy with cisplatin or cetuximab for locally advanced head and neck squamous cell carcinomas: does human papilloma virus play a role? Oral Oncol. [Internet]. 2016;59:50–57. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27424182
- Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. [Internet]. 2009 [cited 2014 Jul 23];62:e1–34. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19631507
- Schuler PJ, Harasymczuk M, Visus C, et al. Phase I dendritic cell p53 peptide vaccine for head and neck cancer. Clin Cancer Res. [Internet]. 2014;20:2433–2444. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24583792
- Bapsy PP, Sharan B, Kumar C, et al. Open-label, multi-center, non-randomized, single-arm study to evaluate the safety and efficacy of dendritic cell immunotherapy in patients with refractory solid malignancies, on supportive care. Cytotherapy. [Internet].2014;16:234–244.
- Lakota J, Gocarova K, Spanik S. Treatment of metastatic head and neck cancer with mesenchymal stem cells combined with prodrug gene therapy. Exp Oncol. [Internet]. 2015;37:298. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26710845
- Kucerova L, Altanerova V, Matuskova M, et al. Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. Cancer Res. 2007;67:6304–6313.
- Jiang P, Zhang Y, Archibald S J, et al. Adoptive cell transfer after chemotherapy enhances survival in patients with resectable HNSCC. Int Immunopharmacol. [Internet]. 2015;28:208–214.
- Lutzky VP, Crooks P, Morrison L, et al. Cytotoxic T cell adoptive immunotherapy as a treatment for nasopharyngeal carcinoma. Clin Vaccine Immunol. [Internet].2014;21:256–259. Available from: http://cvi.asm.org/cgi/doi/10.1128/CVI.00121-13
- Eom H, Choi BK, Lee Y, et al. Phase I clinical trial of 4-1BB-based adoptive T-cell therapy for epstein-barr virus (EBV)-positive Tumors. J Immunother. [Internet]. 2016;39:140–148. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26938947
- Chia W-K, Teo M, Wang -W-W, et al. Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma. Mol Ther. [Internet]. 2014;22:132–139. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1525001616311273
- Huang J, Fogg M, Wirth LJ, et al. Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma. Cancer. [Internet]. 2017;123:2642–2650. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28222215
- Toh H, Hopkins R, Ching Q, et al. Cellular immune biomarkers to prognosticate for survival to adoptive T-cell therapy in advanced nasopharyngeal cancer. J Clin Oncol. 2017;35. abstr 6047. Available from: http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.6047
- Miliotou AN, Papadopoulou LC. CAR T-cell therapy: a new era in cancer immunotherapy. Curr Pharm Biotechnol. [Internet]. 2018;19:5–18. Available from: http://www.eurekaselect.com/161365/article
- Shaikh MH, Clarke DTW, Johnson NW, et al. Can gene editing and silencing technologies play a role in the treatment of head and neck cancer? Oral Oncol. [Internet]. 2017;68:9–19.
- Legut M, Dolton G, Mian AA, et al. CRISPR-mediated TCR replacement generates superior anticancer transgenic t cells. Blood. 2018;131:311–322.
- Hong DS, Butler MO, Sullivan RJ, et al. A phase I single arm, open label clinical trial evaluating safety of MAGE-A10 T in subjects with advanced or metastatic head and neck, melanoma, or urothelial tumors (NCT02989064). J Clin Oncol. 2017;35. abstr TPS3098. Available from: http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.TPS3098
- Lm Technology [Internet]. [ cited 2018 Sep 13]. Available from: https://www.advaxis.com/lm-technology-2/
- Mach N, Vernet R, Belkouch M-C, et al. MVX-ONCO-1 phase 1 final results of the first personalized cell-based immunotherapy using cell encapsulation technology. Ann Oncol. [Internet]. 2016;27: Available from: http://academic.oup.com/annonc/article/doi/10.1093/annonc/mdw378.12/2799841/MVXONCO1-phase-1-final-results-of-the-first
- Lathuilière A, Mach N, Schneider BL. Encapsulated cellular implants for recombinant protein delivery and therapeutic modulation of the immune system. Int J Mol Sci. [Internet]. 2015;16:10578–10600. Available from : http://www.ncbi.nlm.nih.gov/pubmed/26006227
- Tan YS, Sansanaphongpricha K, Prince MEP, et al. Engineering vaccines to reprogram immunity against head and neck cancer. J Dent Res. [Internet]. 2018;97:627–634. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29533731
- Klebanoff CA, Rosenberg SA, Restifo NP. Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat Med. 2016;22:26–36.
- Laccourreye O, Marret G, Rubin F, et al. Ten-year outcome of curative “exclusive” chemotherapy in N0M0 squamous cell carcinoma of the larynx and pharynx with complete clinical response. Head Neck. [Internet]. 2019;1–7. Available from: http://doi.wiley.com/10.1002/hed.25674
- Louis CU, Straathof K, Bollard CM, et al. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother. 2010;33:983–990.
- To WC, Wood BG, Krauss JC, et al. Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: a phase 1 study. Arch Otolaryngol Head Neck Surg. [Internet]. 2000;126:1225–1231. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11031409
- Chua D, Huang J, Zheng B, et al. Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma. Int J Cancer. 2001;94:73–80. [Internet]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11668481
- Decker WK, Da Silva RF, Sanabria MH, et al. Cancer immunotherapy: historical perspective of a clinical revolution and emerging preclinical animal models. Front Immunol. [Internet]. 2017;8:829. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28824608
- Eshhar Z, Waks T, Gross G, et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci. [Internet]. 1993;90:720–724. Available from: http://www.pnas.org/cgi/doi/10.1073/pnas.90.2.720
- Stancovski I, Schindler DG, Waks T, et al. Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. J Immunol. [Internet]. 1993;151:6577–6582. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7902379
- Novartis. Novartis receives first ever FDA approval for a CAR-T cell therapy, KymriahTM (tisagenlecleucel, CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice [Internet]. 2017. [cited 2019 Feb 10]. Available from: https://novartis.gcs-web.com/novartis-receives-fda-approval-for-KymriahTM.
- Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. [Internet]. 2018;378:439–448. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29385370
- Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. [Internet]. 2017;377:2531–2544. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29226797
- Louis CU, Savoldo B, Dotti G, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. [Internet]. 2011;118:6050–6056. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21984804
- Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. [Internet]. 2011;29:917–924. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21282551
- Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. [Internet]. 2010;363:411–422. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20818862
- Filley AC, Henriquez M, Dey M. CART immunotherapy: development, success, and translation to malignant gliomas and other solid tumors. Front Oncol. [Internet]. 2018;8:1–19. Available from: https://www.frontiersin.org/article/10.3389/fonc.2018.00453/full.
- Overwijk WW, Wang E, Marincola FM, et al. Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors. J Immunother Cancer. [Internet]. 2013;1:11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24829748
- Tao JJ, Schram AM, Hyman DM. Basket studies: redefining clinical trials in the era of genome-driven oncology. Annu Rev Med. [Internet]. 2018;69:319–331. Available from: http://www.annualreviews.org/doi/10.1146/annurev-med-062016-050343
- Renfro LA, Sargent DJ. Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples. Ann Oncol Off J Eur Soc Med Oncol. [Internet]. 2017;28:34–43. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28177494.
- Ghosh P, Liu L, Senchaudhuri P, et al. Design and monitoring of multi-arm multi-stage clinical trials. Biometrics. [Internet]. 2017;73:1289–1299. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28346823